 |
|
|
|
|
|
NEWS RELEASE:
FOR IMMEDIATE RELEASE:
|
Beth Frost-Johnson, Sr. VP of Marketing
Merge Healthcare
414.977.4254
bfrost@merge.com
|
|
Richard Linden, President and CEO
Merge Healthcare
414.977.4000
rlinden@merge.com
|
|
MERGE HEALTHCARE HIRES ROBERT J. WHITE AS PRESIDENT OF MERGE EMED
Milwaukee, WI, April 3, 2006 – Merge Technologies Incorporated, d.b.a. Merge Healthcare (NASDAQ: MRGE; TSX: MRG), today announced that Robert J. White has joined the Company as President of Merge eMed. Merge eMed is a Merge Healthcare division that serves the end-user medical imaging and healthcare information systems market in the U.S. David Noshay, formerly President of Merge eMed, will lead Merge Healthcare’s strategic business development initiatives including mergers, acquisitions, and associated business integration activities.
Bob has more than 20 years of healthcare industry experience. Most recently, he was Chief Operating Officer of SourceOne Healthcare Technologies, where he led the company's overall product and services strategy, business development efforts, and operational execution. SourceOne Healthcare Technologies is a leading provider of radiology and digital imaging solutions and services to various healthcare markets, with particular focus on building long-term relationships with hospitals, imaging centers, and specialty clinics. Prior to joining SourceOne, Bob spent 15 years at IBM, where he served in various senior executive and sales/marketing roles, including Global Marketing Executive for IBM’s multi-billion dollar healthcare business with responsibility for global marketing, business development and strategy. Bob has also held a variety of senior executive sales and marketing positions with the software technology and service provider firms Chemdex and Accelrys.
"We are pleased to welcome Bob to the Merge Healthcare team," said Richard Linden, Merge Healthcare President and CEO. "Bob’s leadership, healthcare industry expertise, sales and marketing experience, and customer-centric focus will be instrumental in leading Merge eMed in the coming years. Through our strategic relationship with SourceOne, we were fortunate to work with Bob and experience first hand his customer service orientation and ability to focus a large organization on the delivery of consistent quality and growing value to its various stakeholders."
"Additionally, I am pleased to announce that David Noshay will assume responsibilities for our strategic business development initiatives. Mergers and acquisitions, along with the associated business integration activities, will continue to play an important role in ensuring that our capabilities meet the needs of our customers and the new markets we pursue."
Linden concluded, "As the landscape of the healthcare industry continues to evolve, we are constantly striving to enhance the long-term value that Merge Healthcare brings to our customers, investors and employees. These two leadership changes strengthen the operations of Merge eMed, and enhance our ability to deliver on this strategic goal."
# # #
Merge Healthcare is a market leader in the development and delivery of medical imaging and information
management software and services. Our innovative software solutions use leading-edge imaging software
technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve
our customers' productivity and enhance the quality of patient care they provide. For additional information,
visit our website at www.merge.com.
Merge eMed, a Merge Healthcare company,is focused on accelerating productivity for radiology departments and specialty practices, imaging centers and hospitals. By combining sophisticated RIS, PACS, advanced visualization and clinical imaging applications, Merge eMed delivers integrated end-to-end software solutions and professional services that are transforming the way our customers interact with referring physicians, manage their workflow, position their businesses in their markets and deliver imaging and information services to their customers. For additional information, visit our website at www.merge-emed.com.
Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words: guidance, believes, intends, anticipates, expects, and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements based on a number of factors, including, but not limited to, risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, unexpected outcomes to any pending or future litigation, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect any future events or circumstances.
|
Attn: Beth Frost-Johnson
Merge Healthcare
6737 West Washington St.
Suite 2250
Milwaukee, WI 53214
|
|
|
|
|
|
| Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.
|
|
|
